Risk of breast cancer mutations underestimated for Asian women, Stanford study shows

September 12, 2008

STANFORD, Calif. - Oncologist Allison Kurian, MD, and her colleagues at the Stanford University School of Medicine were perplexed. Computer models designed to identify women who might have dangerous genetic mutations that increase their risk of breast and ovarian cancer worked well for white women. But they seemed to be less reliable for another ethnic group.

"We've been repeatedly surprised when Asian women who the models predicted would probably not have the mutations do in fact have them," said Kurian. She recently showed that in a head-to-head comparison between whites and Asians, two of the most commonly used models failed in predicting the presence of mutations in almost half of the Asian women studied.

"Doctors and patients should have a higher level of suspicion when using these prediction models in Asian women, because they under-predicted the true number of clinically important mutations," said Kurian. "We may have to consider more subtle patterns of family cancer history when considering genetic testing in this ethnic group."

Kurian, assistant professor of oncology and of health research and policy, is the first author of the research, which was published online in the Journal of Clinical Oncology on Sept 8.

Mutations in two genes - BRCA1 and BRCA2 - are strongly associated with the development of breast or ovarian cancer in carriers. However, not every woman with a family history of cancer or who develops these cancers has these mutations.

To determine who should be tested for the mutations, genetic counselors frequently use computer models that assess specific variables for each woman, such as the number of relatives affected by breast and ovarian cancer, the age of each relative at onset of the condition and how closely the woman is related to her affected relatives. Those women deemed by the models to be likely carriers of these mutations are referred for testing of their BRCA1 and BRCA2 genes.

Kurian and her colleagues used two of the most widely used computer models, named BRCAPRO and Myriad II, to predict the presence of the mutations in 200 white women and 200 Asian-American women at cancer genetics clinics in four locations: Stanford, the University of California-San Francisco, Queen's Medical Center in Honolulu and the British Columbia Cancer Center in Vancouver. They sequenced the BRCA1 and BRCA2 genes of all of the study subjects and compared them to the models' predictions.

The researchers found that the models were highly accurate in predicting the presence of mutations in white women; one program identified 24 of the 25 women with BRCA1 or BRCA2 mutations and the other identified all 25. However, both programs performed much worse in predicting the 49 Asian women in the study sample with mutations. One program predicted that only 25 of the 49 women would carry mutations, while the other recommended testing of 26 women.

"It's clear that these models are far from foolproof," said Kurian, who is also a member of the Stanford Cancer Center. "These results emphasize the need for expert evaluation by a genetics professional to guide all clinical genetic testing."

Because the Asian and white women reported similar numbers of affected relatives on average, it's possible that fewer Asians with the mutations go on to develop cancer. In that case, the family history would be a less accurate way to determine the presence of the mutations. Kurian and her colleagues are collaborating with researchers in Hong Kong to investigate these and other alternatives.

The study results point out the need for further investigation into the genetic variability of different ethnic groups. In addition to previously identified, clinically important mutations of the genes, the researchers identified more "variants of unknown significance" in the BRCA1 and BRCA2 genes of Asian women than in white women.

Many of these variants probably don't have any clinical effect," said Kurian. "We know a lot more about the normal variability of these genes in white women. Many of these variants are probably just normal for members of a particular ethnic group, but we haven't studied enough people in ethnic minority groups to know for sure, and further research needs to be done to distinguish variants of uncertain significance from truly harmful mutations."

Stanford University Medical Center

---

---

	MRI best for carriers of BRCA gene mutations: study shows MRI detects more breast cancers in this population than do ultrasound or ... An article from: Family Practice News by Betsy Bates (Author) This digital document is an article from Family Practice News, published by International Medical News Group on December 1, 2004. The length of the article is 979 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: MRI best for carriers of BRCA gene mutations: study shows MRI detects more breast cancers in this population than do ultrasound or mammography.(Women's Health)(Magnetic resonance imaging) Author: Betsy Bates Publication: Family Practice News (Magazine/Journal) Date: December 1, 2004 Publisher: International Medical News Group Volume: 34 Issue: 23 Page:...
	Questions & Answers About Triple Negative Breast Cancer by Carey K. Anders (Author), Nancy U Lin (Author) Approximately10-20% Of Breast Cancer Patients Are Diagnosed With Triple-Negative Breast Cancer. Questions & Answers About Triple Negative Breast Cancer Provides Authoritative And Practical Answers To The Most Common Questions Asked By Patients And Their Loved Ones. This Easy-To-Read Book Is A Comprehensive Guide To The Basics Of Triple Negative Breast Cancer, Risk Factors And Prevention, Diagnosis, Treatment, Survivorship, And Life After Diagnosis. Written By Renowned Medical Experts On The Topic, Questions & Answers About Triple Negative Breast Cancer Is An Invaluable Resource For Anyone Coping With The Physical And Emotional Turmoil Of This Challenging Type Of Breast Cancer.
	Confronting Hereditary Breast and Ovarian Cancer: Identify Your Risk, Understand Your Options, Change Your Destiny (A Johns Hopkins Press Health Book) by Sue Friedman (Author), Rebecca Sutphen (Author), Kathy Steligo (Author), Mark H. Greene (Foreword) "Be informed. Be empowered. Be well."If you are concerned that the cancer in your family is hereditary, you face difficult choices. Should you have a blood test that may reveal whether you have a high likelihood of disease? Do you preemptively treat a disease that may never develop? How do you make decisions now that will affect the rest of your life? This helpful, informative guide answers your questions as you confront hereditary breast and ovarian cancer.Developed by Facing Our Risk of Cancer Empowered (FORCE), the nation’s only nonprofit organization dedicated to supporting families affected by hereditary breast and ovarian cancer, this book stands alone among breast and ovarian cancer resources. Equal parts health guide and memoir, it defines complex issues facing previvors and...
	Dear God, They Say It's Cancer: A Companion Guide for Women on the Breast Cancer Journey by Janet Thompson (Author) A Friend to Help You Through... No matter where you are in your breast cancer journey, this book is the companion you need. Whether... you've just heard the dreaded diagnosis for the first time you're in the middle of decisions and treatments you're experiencing the disappoint of recurrence or you're several years beyond the initial trauma... No matter where you are in that journey, you need someone who understands. You need a trusted friend to walk along beside, someone who's gone before you. You'll find that friend between the pages of this book. This book is yours to use in whatever way serves you best. You can start in the beginning and work your way through, or you can use the detailed table of contents to help you find just what you need for what you are...
	Preferential Maternal LOH in the IGF2R Gene in Breast Cancer: Mutations And The Role Of Epigenetics by Marie Demian (Author) Tumors develop and progress as a result of alterations in oncogene and tumor suppressor genes. Knudson's two hit model predicts that cancer arises when both alleles of a tumor suppressor gene are inactivated. The insulin-like growth factor 2 receptor gene (IGF2R) is known to be a tumor suppressor for breast cancer,as mutations inactivating both alleles have been found in these tumors,consistent with its known functions in degradating insulin-like growth factor 2 (IGF2) and activating transforming growth factor ?1 (TGF- ?1),a growth inhibitor. Tumor suppressors can be inactivated by several means,such as genomic imprinting (a preferential silencing of a particular parental chromosome),large deletions resulting in loss of heterozygosity (LOH),and point mutations. In both humans and...
	Living Through Breast Cancer by Carolyn M. Kaelin (Author), Francesca Coltrera (Author) A compassionate and uniquely authoritative guide to surviving breast cancer Dr. Carolyn M. Kaelin is nationally recognized as a leading expert on breast cancer. At the age of 42, this highly respected cancer surgeon and the director of the prestigious Comprehensive Breast Health Center at Brigham and Women's Hospital, one of Harvard Medical School's main hospitals, had a young family and demanding career. When she discovered that she had breast cancer, she was suddenly transformed from doctor to patient--and learned firsthand just how this terrible disease makes women question their sense of self. Now, following a mastectomy and an ongoing course of chemotherapy, her prognosis is good and her passion and commitment to helping other women with breast cancer is greater than ever. In a...
	Prophylactic Mastectomy: Insights from Women Who Chose to Reduce Their Risk by Andrea Patenaude (Author) Author Andrea Farkas Patenaude, a clinical psychologist at the Dana-Farber Cancer Institute, has spent much time talking with women who decided to have risk-reducing or prophylactic mastectomy rather than undergo a lifetime of repeated screenings—a strategy that can help to detect cancers early, but cannot prevent breast cancer. In Prophylactic Mastectomy: Insights from Women Who Chose to Reduce Their Risk, Patenaude shares many candid stories from these women and documents the risks and benefits of this decision. The potential emotional trauma and lifelong effects on self-concept, body image, and sexual function for those who choose the surgery are profound. While the risks involved are great, these interviews also demonstrate the relief many women find in making this powerful...
	New tests urged for breast cancer gene mutations.(Gynecology): An article from: OB GYN News by Deeanna Franklin (Author) This digital document is an article from OB GYN News, published by Thomson Gale on April 15, 2006. The length of the article is 676 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: New tests urged for breast cancer gene mutations.(Gynecology) Author: Deeanna Franklin Publication: OB GYN News (Magazine/Journal) Date: April 15, 2006 Publisher: Thomson Gale Volume: 41 Issue: 8 Page: 19(1) Distributed by Thomson...
	QuickFACTS Breast Cancer: What You Need to Know-NOW by American Cancer Society (Author) Covering everything from breast cancer risk factors to living well after treatment, this pocket-sized reference provides critical questions to ask a health-care team; presents the latest guidelines for diagnosis, staging, and treatment; and details what to expect after treatment. This comprehensive yet concise guide is the fastest way to get evidence based content on the disease and includes an advanced dictionary of breast cancer-related terms. It educates and empowers both patients and their caregivers to combat breast cancer from the start.
	Breast Fitness: An Optimal Exercise and Health Plan for Reducing Your Risk of Breast Cancer by Anne McTiernan (Author), Dr. Julie Gralow (Author), Lisa Talbott MPH (Author) Never before has a book so clearly detailed how exercise can reduce the risk for and recurrence of breast cancer, and how women can incorporate a safe and effective exercise program into their lives to fight against the disease. In clear, accessible language, the expert authors explain: *How to ascertain your breast cancer risk factors *What you can do NOW to prevent Breast Cancer *Detailed diet and exercise programs that will keep you healthy and can save your life *How to detect breast cancer early *Your best lifestyle choices for surviving--and thriving--after diagnosis, and practical steps to maximize your chances of the cancer never coming back.